Ann: Investor Update, page-45

First 45 Last

Share
Profile

Follow
80/20

101 Posts.

8

06/09/20

01:21

Post #: 47118386
Share

Originally posted by 123John: ↑

Just finished reading through the various posts but more importantly, well at least in my opinion the medical presentations of their clinical trials.

What strikes me as very odd is the sample size for approval as a medical device seems to only be 50 recruits, is this normal for medical devices?

In comparison to drugs a phase 2 or phase 3 trial of a drug will often run 200-300 recruits per study arm to get a statistically meaning result for efficacy and superiority.

Looking at the New Zealand estimate of the addressable market suggests that Oncosil would be priced at $25k USD per patient, which would put it on par for current costs of private chemotherapy. $43M/1719 patients p.a. Based on the Oncosil presentation figures. Is this what Oncosil projects to take in as addressable revenue extra over to the costs of administering the device and cost of the chemo drugs?

The PanCO study is Oncosil + chemo open drugs, which would put the likely cost of total treatment around $60k USD if paid for privately and the $25k USD in the presentation does not include the cost of chemo.

In NZ, as an example, pharmac funding has not yet been approved or even appears to be under consideration. So the addressable market would be much smaller than suggested until the price drops for the combined treatment.

Extrapolating to the global addressable market using NZ as a baseline, it it likely 5% of the market will be able to self fund until efficacy is widely established so that private insurance is willing to cover the costs. Addressable market in the short term of $150M USD.

Will keep an eye on this one, given the lack of peer reviewed studies and the small sample size of the trials. I think there is a real the risk of not being able to commercialise quickly and therfore further dilution and capital raises to fund marketing and pro bono treatment to establish a successful track record of treated patients.

Cost of trying to sell the product to oncologists and establish in the market will be significant. Not happy to buy at current price, but might look at putting in a limit buy at a price I'm happy at next week to test the waters.

Expand

hum .. I am not an expert. but no phase 2,3 trials also made me surprised. but I saw in their investor updates around that time that CE required only 20 tests. they did ~ 50.

OSL Price at posting: 13.5¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

SS1

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

LU7

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

LRV

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

RCE

Recce's R327 found effective against E.coli during clinical trial

There are more pages in this discussion • 51 more messages in this thread...

First 45 Last

Add OSL (ASX) to my watchlist

(20min delay)
Last 0.5¢		Change 0.001(11.1%)		Mkt cap ! $16.66M

Open	High	Low	Value	Volume
0.5¢	0.5¢	0.5¢	$16.97K	3.406M

Buyers (Bids)

No.	Vol.	Price($)
32	24223265	0.4¢

Sellers (Offers)

Price($)	Vol.	No.
0.5¢	6803713	11

View Market Depth

No.	Vol.	Price($)
32	24223265	0.004
9	5173547	0.003
6	5457516	0.002
4	7800000	0.001
0	0	0.000

Price($)	Vol.	No.
0.005	6803713	11
0.006	20507648	25
0.007	24904167	20
0.008	9543848	10
0.009	12462253	5

Last trade - 13.09pm 28/06/2024 (20 minute delay)

OSL (ASX) Chart

Ann: Investor Update, page-45

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Recce's R327 found effective against E.coli during clinical trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Investor Update, page-45

Top Stories

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Recce's R327 found effective against E.coli during clinical trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News